General Information of Drug Transporter (DT)
DT ID	DTD0247 Transporter Info
Gene Name	SLC29A1
Protein Name	Equilibrative nucleoside transporter 1
Gene ID	2030
UniProt ID	Q99808
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs747199
Site of GPD	chr6:44226608 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C
Minor Allele Frequency	C=0.1478/740 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Gemcitabine	Drug Info	Breast Neoplasm	Correlated with the decreased drug response in patients (compare with Allele C)		[ 1]
Paclitaxel	Drug Info	Breast Neoplasm	Correlated with the decreased drug response in patients (compare with Allele C)		[ 1]
Gemcitabine	N.A.	Neutropenia	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.		[ 1]
Paclitaxel	N.A.	Neutropenia	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.		[ 1]
Gemcitabine	N.A.	Breast Neoplasms	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.		[ 1]
Paclitaxel	N.A.	Breast Neoplasms	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotype CC is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype GG.		[ 2]
Mercaptopurine	N.A.	Agranulocytosis	Genotype CC is associated with decreased risk of Agranulocytosis and Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CG + GG.		[ 3]
Mercaptopurine	N.A.	Leukopenia	Genotype CC is associated with decreased risk of Agranulocytosis and Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CG + GG.		[ 3]
Methotrexate	N.A.	Agranulocytosis	Genotype CC is associated with decreased risk of Agranulocytosis and Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CG + GG.		[ 3]
Methotrexate	N.A.	Leukopenia	Genotype CC is associated with decreased risk of Agranulocytosis and Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CG + GG.		[ 3]
Cytarabine	N.A.	Drug Toxicity	Genotype CC is not associated with increased Drug Toxicity when treated with cytarabine as compared to genotype GG.		[ 4]
Gemcitabine	N.A.	Breast Neoplasms	Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.		[ 1]
Paclitaxel	N.A.	Breast Neoplasms	Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.		[ 1]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotype CG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype GG.		[ 2]
Gemcitabine	N.A.	Breast Neoplasms	Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.		[ 1]
Paclitaxel	N.A.	Breast Neoplasms	Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Gemcitabine	N.A.	Neutropenia	Genotype GG is not associated with metabolism of gemcitabine as compared to genotypes CC + CG.		[ 5]
Gemcitabine	N.A.	Breast Neoplasms	Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.		[ 1]
Paclitaxel	N.A.	Breast Neoplasms	Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.		[ 1]
Genotypes CG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Azathioprine	N.A.	Neutropenia	Genotypes CG + GG is associated with increased likelihood of Neutropenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype CC.		[ 6]
Genetic Polymorphism	rs760370
Site of GPD	chr6:44233216 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.2997/1501 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Gemcitabine	Drug Info	Breast Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 1]
Paclitaxel	Drug Info	Breast Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 1]
Gemcitabine	N.A.	Neutropenia	Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.		[ 1]
Paclitaxel	N.A.	Neutropenia	Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.		[ 1]
Gemcitabine	N.A.	Neoplasms	Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         14 Drugs in Total
Gemcitabine	Drug Info	Pancreatic Neoplasm	Correlated with the decreased drug response in patients (compare with genotypes AA + AG)		[ 7]
Ribavirin	Drug Info	Chronic Hepatitis C	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 8]
Peginterferon alfa-2A	Drug Info	Chronic Hepatitis C	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 8]
Peginterferon alfa-2B	Drug Info	Chronic Hepatitis C	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 8]
Gemcitabine	N.A.	Neutropenia	Genotype GG is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.		[ 7]
Peginterferon Alfa-2a	N.A.	Neutropenia	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.		[ 8]
Peginterferon Alfa-2b	N.A.	Neutropenia	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.		[ 8]
Ribavirin	N.A.	Neutropenia	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.		[ 8]
Peginterferon Alfa-2a	N.A.	Chronic Hepatitis C Virus Infection	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.		[ 8]
Peginterferon Alfa-2b	N.A.	Chronic Hepatitis C Virus Infection	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.		[ 8]
Ribavirin	N.A.	Chronic Hepatitis C Virus Infection	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.		[ 8]
Gemcitabine	N.A.	Neoplasms	Genotype GG is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the GG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the GG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Trifluridine	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype AA)		[ 9]
Tipiracil Hydrochloride	N.A.	Neutropenia	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.		[ 9]
Trifluridine	N.A.	Neutropenia	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.		[ 9]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.		[ 9]
Tipiracil hydrochloride	N.A.	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype AA)		[ 9]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Peginterferon Alfa-2a	N.A.	Chronic Hepatitis C Virus Infection	Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.		[ 8]
Peginterferon Alfa-2b	N.A.	Chronic Hepatitis C Virus Infection	Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.		[ 8]
Ribavirin	N.A.	Chronic Hepatitis C Virus Infection	Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.		[ 8]
Gemcitabine	N.A.	Neoplasms	Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the AA genotype may have a worse response to tipiracil hydrochloride and trifluridine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the AA genotype may have a worse response to tipiracil hydrochloride and trifluridine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Peginterferon Alfa-2a	N.A.	Chronic Hepatitis C Virus Infection	Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.		[ 8]
Peginterferon Alfa-2b	N.A.	Chronic Hepatitis C Virus Infection	Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.		[ 8]
Ribavirin	N.A.	Chronic Hepatitis C Virus Infection	Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.		[ 8]
Gemcitabine	N.A.	Neoplasms	Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Genetic Polymorphism	rs9394992
Site of GPD	chr6:44228255 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.2973/1489 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Gemcitabine	Drug Info	Pancreatic Neoplasm	Irrelevant to the increased drug response in patients (compare with Genotypes CT + TT)		[ 7]
Gemcitabine	N.A.	Neutropenia	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.		[ 7]
Gemcitabine	N.A.	Pancreatic Neoplasms	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the CC genotype may have a decreased response to tipiracil hydrochloride and trifluridine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the CC genotype may have a decreased response to tipiracil hydrochloride and trifluridine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Trifluridine	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype CC)		[ 9]
Gemcitabine	Drug Info	Pancreatic Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotype CC)		[ 7]
Gemcitabine	N.A.	Neutropenia	Genotypes CT + TT are associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.		[ 7]
Tipiracil Hydrochloride	N.A.	Neutropenia	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.		[ 9]
Trifluridine	N.A.	Neutropenia	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.		[ 9]
Gemcitabine	N.A.	Pancreatic Neoplasms	Genotypes CT + TT are associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.		[ 9]
Tipiracil hydrochloride	N.A.	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype CC)		[ 9]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Gemcitabine	N.A.	Pancreatic Neoplasms	Patients with the CT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the CT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the CT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Gemcitabine	N.A.	Pancreatic Neoplasms	Patients with the TT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.		[ 7]
Tipiracil Hydrochloride	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the TT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Trifluridine	N.A.	Colorectal Neoplasms	Patients with colorectal cancer and the TT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.		[ 9]
Genetic Polymorphism	rs3734703
Site of GPD	chr6:44233997 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.9300/1840 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Cytarabine	N.A.	Neutropenia	Allele A is associated with increased response to cytarabine in people with Leukemia, Myeloid, Acute as compared to allele C.		[ 10]
Genetic Polymorphism	rs324148
Site of GPD	chr6:44228841 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.2060/407 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Neutropenia	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.		[ 7]
Genetic Polymorphism	rs3778504
Site of GPD	chr6:44221463 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9550/1889 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Neutropenia	Genotypes AA + AG are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.		[ 11]
References
1	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer. 2014 Mar;50(4):698-705.
2	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
3	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119-34.
4	Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics. 2011 Apr;12(4):503-14.
5	SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer. 2014 Jan 21;110(2):304-12.
6	Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine. Inflamm Bowel Dis. 2015 Dec;21(12):2897-908.
7	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15;116(22):5325-35.
8	Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis. 2010 Oct 15;202(8):1185-91.
9	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 Nov;86:197-206.
10	SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia. Cancer Chemother Pharmacol. 2016 Sep;78(3):533-40.
11	Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Pharmacogenomics. 2012 Jul;13(9):1023-35.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.